PO.MCB11.01 · 分子与细胞生物学
NF1缺陷的HER2阳性乳腺癌在有丝分裂和药理学应激下微管晶格损伤的定量分析
Quantitative analysis of microtubule lattice damage in NF1-deficient HER2-positive breast cancer under mitotic and pharmacological stress
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
我们对微管(MT)动力学的理解近期已扩展到包括晶格内部的重塑事件,即机械应激产生的不连续性通过晶格内微管蛋白的掺入和EB1的重新分布得以修复。目前仅知两种因子——CLASP1和SSNA1——能识别和调节这种形式的MT损伤。目前尚未建立可靠估计MT损伤和修复的方法,使其对肿瘤发生和抗癌药物活性的贡献尚不明确。在我们先前的工作中,我们证明抑癌基因NF1(一种新的微管相关蛋白(MAP))的缺失会导致HER2阳性乳腺癌细胞中MT损伤增加。这继而导致有丝分裂缺陷(可能促进肿瘤发生),但也使细胞对美登素类药物(如DM1)敏感化,DM1是一类常用于抗体药物偶联物(ADC,T-DM1和Mirvetuximab Soravtansine)的药物。为研究药理学和机械应激下的MT损伤和修复,我们分析了EB1的分布,EB1通常局限于生长中的MT末端,但已知在结构破坏或修复因子(如CLASP)被消除时会沿MT主体重新分布。我们开发了一种新方法,系统性地量化单根MT上的EB1和微管蛋白信号。为达到解析EB1所需的空间精度,我们将DeepSIM和膨胀显微镜(ExM)与两种互补的分析策略相结合:使用SNT ImageJ插件(专为神经突追踪设计)进行手动3D MT追踪,以及用于MT分割和EB1信号提取的自动化流程。在DM1处理后,EB1显示出从末端到MT主体的渐进性重新定位,这与其在末端既定的解聚活性之外还存在部分晶格内破坏相一致。在NF1缺陷细胞中,晶格内EB1的初始增加之后是整体EB1信号的急剧减少和明显的MT碎裂,表明DM1诱导的MT断裂和解聚更快;这一现象通过NF1的重新表达而被消除。这些结果直接表明,在NF1缺陷细胞中更为显著的MT修复失败如何产生更多的晶格内DM1结合位点,从而解释了敏感性的增加。在有丝分裂中,NF1缺陷细胞在MT主干上显示出强烈增加的EB1信号,这与强机械应激下修复失败相一致。EB1主干定位和有丝分裂缺陷(染色体错误分离、非整倍体)通过NF1的重新表达得以挽救。通过建立在单根MT分辨率下测量EB1重新分布的定量框架,我们的研究提供了一种此前无法获得的监测癌细胞中晶格内损伤的策略。这些发现首次确立了未修复的MT损伤与染色体不稳定之间的直接因果联系,为理解美登素类药物的作用机制提供了新模型。
查看英文原文 English abstract
Our understanding of microtubule (MT) dynamics has recently expanded to include remodeling events within the lattice, where mechanical stress generates discontinuities repaired through intra-lattice tubulin incorporation and EB1 redistribution. Only two factors, CLASP1 and SSNA1, are known to recognize and modulate this form of MT damage. Methods to reliably estimate MT damage and repair are not established, leaving their contribution to tumorigenesis and anticancer drug activity unclear. In our previous work, we demonstrated that loss of the tumor suppressor NF1, a new MT-associated protein (MAP), leads to increased MT damage in HER2-positive breast cancer cells. This in turn causes mitotic defects (potentially contributing to tumorigenesis) but also sensitization to maytansinoids like DM1, a drug class frequently used in Antibody-Drug Conjugates (ADC, T-DM1 and Mirvetuximab Soravtansine). To investigate MT damage and repair upon pharmacological and mechanical stress, we analyzed the distribution of EB1, normally confined to growing MT tips but known to redistribute along the MT body upon structural disruption or when repair factors like CLASP are ablated. We developed a novel method to systematically quantify EB1 and tubulin signal along single MTs. To achieve the spatial precision required to resolve EB1 we combined DeepSIM and expansion microscopy (ExM) with two complementary analytical strategies: manual 3D MT tracing using SNT ImageJ plugin (designed for neurite tracing) and an automated pipeline for MT segmentation and EB1 signal extraction. Upon DM1 treatment, EB1 showed progressive re-localization from the tip to the MT body, consistent with partial intra-lattice disruption in addition to its established de-polymerizing activity at the tip. In NF1 deficient cells, an initial increase in intra-lattice EB1 was followed by a sharp reduction in overall EB1 signal and pronounced MT fragmentation, indicating faster DM1-induced MT fracturing and depolymerization; this was abolished by NF1 re-expression. These results directly show how failed MT repair, more prominent in NF1 deficient cells, creates further intra-lattice DM1 binding sites explaining increased sensitivity. In mitosis, NF1 deficient cells showed strongly increased EB1 signal on the MT shaft, consistent with failure of repair under strong mechanical stress. EB1 shaft localization and mitotic defects (chromosome missegregation, aneuploidy) were rescued by NF1 re-expression.By establishing a quantitative framework to measure EB1 redistribution at single MT resolution, our study provides a previously unavailable strategy to monitor intra-lattice damage in cancer cells. These findings establish for the first time a direct causative link between unrepaired MT damage and chromosomal instability, providing a new model to understand maytansinoid mechanism of action.
利益披露 Disclosure
E. Messuti, None..
A. Castiglioni, None..
S. Rodighiero, None..
A. Dondi, None..
B. Achutti Duso, None..
L. Mazzarella, None.